» Authors » Daniel J Feaster

Daniel J Feaster

Explore the profile of Daniel J Feaster including associated specialties, affiliations and a list of published articles. Areas
Snapshot
Articles 217
Citations 3162
Followers 0
Related Specialties
Top 10 Co-Authors
Published In
Affiliations
Soon will be listed here.
Recent Articles
1.
Harkness A, Morales V, Grealis K, Reyes N, Feaster D, Safren S, et al.
AIDS Behav . 2025 Jan; PMID: 39881020
Pre-exposure prophylaxis (PrEP), an effective biomedical prevention intervention, is not sufficiently reaching populations experiencing high HIV incidence. Behavioral health (BH) treatment addressing mental health and substance use similarly requires increased...
2.
Zheng T, Keyes K, Ji S, Calderon A, Wu E, Doogan N, et al.
Drug Alcohol Depend . 2025 Jan; 267:112548. PMID: 39799847
Introduction: Prevalence estimates of opioid use disorder (OUD) at local levels are critical for public health planning and surveillance, yet largely unavailable across the US especially at the local county...
3.
Reyes N, Lozano A, Weinstein E, Feaster D, Harkness A
AIDS Patient Care STDS . 2025 Jan; 39(2):70-79. PMID: 39773003
Pre-exposure prophylaxis (PrEP) is an effective HIV prevention tool available in several modalities (e.g., daily oral, injectable, implants, rectal douching). The Ending the HIV Epidemic (EHE) initiative, a national initiative...
4.
Tross S, Laschober T, Paschen-Wolff M, Ertl M, Nelson C, Wright L, et al.
AIDS Behav . 2024 Dec; PMID: 39739284
In Southern U.S. states with high HIV incidence and low HIV Pre-Exposure Prophylaxis (PrEP) uptake, enhanced efforts to increase interest in and willingness to use PrEP are needed. This implementation...
5.
Balise R, Hu M, Calderon A, Odom G, Brandt L, Luo S, et al.
PLoS One . 2024 Nov; 19(11):e0312695. PMID: 39570967
Several large-scale, pragmatic clinical trials on opioid use disorder (OUD) have been completed in the National Drug Abuse Treatment Clinical Trials Network (CTN). However, the resulting data have not been...
6.
Goddard-Eckrich D, Grealis K, El-Bassel N, Lounsbury D, Dsouza N, Bhuiyan J, et al.
J Subst Use Addict Treat . 2024 Nov; 169:209566. PMID: 39527983
Introduction: Little is known about how pharmacists' attitudes and stigma toward naloxone and Medication for opioid use disorder (MOUD) influence effective linkage to treatment. We examine the psychometrics of a...
7.
Freisthler B, Chahine R, Villani J, Chandler R, Feaster D, Slavova S, et al.
JAMA Netw Open . 2024 Oct; 7(10):e2440006. PMID: 39432308
Importance: The HEALing Communities Study (HCS) evaluated the effectiveness of the Communities That HEAL (CTH) intervention in preventing fatal overdoses amidst the US opioid epidemic. Objective: To evaluate the impact...
8.
Freeman P, Walley A, Winhusen T, Oga E, Villani J, Hunt T, et al.
Am J Public Health . 2024 Oct; 115(1):83-94. PMID: 39388670
To determine whether the Communities That HEAL (CTH) intervention is effective in increasing naloxone distribution compared with usual care. The HEALing (Helping to End Addiction Long-Term) Communities Study (HCS) is...
9.
Christine P, Chahine R, Kimmel S, Mack N, Douglas C, Stopka T, et al.
JAMA Netw Open . 2024 Aug; 7(8):e2425999. PMID: 39102264
Importance: Local-level data are needed to understand whether the relaxation of X-waiver training requirements for prescribing buprenorphine in April 2021 translated to increased buprenorphine treatment. Objective: To assess whether relaxation...
10.
Liu J, Feaster D, Shahid N, Lazarus K, Boga D, Willie P, et al.
J Racial Ethn Health Disparities . 2024 Aug; PMID: 39102174
Assessing measurement invariance and the interplay of discrimination, microaggressions, and resilience among Black women living with HIV (BWLWH) across time utilizing latent class and repeated measure analysis may provide novel...